Yoshimura N, Kobayashi Y, Nakamura K, Yamagishi H, Oka T
Second Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto City, Japan.
Transplantation. 1999 Jan 15;67(1):45-53. doi: 10.1097/00007890-199901150-00007.
Tissue factor (TF) is an initiation factor for blood coagulation, and its expression is induced on macrophages and endothelial cells during the inflammatory or immune responses. In a previous study, we reported the significance of TF expression in hepatic ischemic reperfusion injury using a rat model. Recently, tissue factor pathway inhibitor (TFPI) has been discovered, and the effect of TFPI has been assessed in vivo. In this study, therefore, we studied the effect of TFPI on hepatic ischemic reperfusion injury of the rat.
After laparotomy of Lewis rats, the branches of the hepatic artery and portal vein leading to the median, left, and caudate lobes of the liver were clamped. The liver was reperfused after 120 or 180 min of ischemia. Simultaneously, recombinant human TFPI (4 mg/kg) was injected via a superiomesenteric vein. Rats were sacrificed at 5, 12, and 24 hr after reperfusion, and liver tissues were harvested. TF expression was studied by immunohistochemical staining with the monoclonal antibody (HTF-K108).
Survival rates over a 5-day period were examined after the ischemic time of 120 and 180 min. Seven of 10 rats in the 120-min ischemia group (n=10), and only 1 (10%) rat of 10 in the 180-min ischemia group (n=10) survived. However, by the treatment with TFPI, all of the rats in the 120-min ischemia group (n=10), and six rats in the 180-min ischemia group (n=10) survived (P<0.05). The serum concentrations of alanine aminotransferase (ALT) and thrombin-antithrombin complex (TAT) before ischemia were 30.0+/-2.3 IU/L and 4.7+/-1.4 ng/ml, respectively (n=5). These levels showed a peak at 3-5 hr after reperfusion (ALT: 13909+/-1900 IU/L, TAT: 30.4+/-7.0 ng/ml) (P<0.01). However, both peak levels were decreased by the treatment with TFPI (ALT: 6017+/-1290 IU/L, TAT: 5.4+/-2.1 ng/ml) (P<0.01). Although TF was strongly stained on endothelial cells and Kupffer cells accumulating to the site of the necrosis in the control group, the area of the necrosis and the grade of TF staining were significantly reduced in the TFPI-treated group.
These results indicated that TFPI strongly inhibited the injury of the ischemic reperfusion, and confirmed that TF played a pivotal role in the development of ischemic reperfusion injury.
组织因子(TF)是血液凝固的起始因子,在炎症或免疫反应过程中,其表达在巨噬细胞和内皮细胞上被诱导。在先前的一项研究中,我们使用大鼠模型报道了TF表达在肝缺血再灌注损伤中的意义。最近,组织因子途径抑制剂(TFPI)已被发现,并且TFPI的作用已在体内进行了评估。因此,在本研究中,我们研究了TFPI对大鼠肝缺血再灌注损伤的影响。
对Lewis大鼠进行剖腹手术后,夹住通向肝中叶、左叶和尾状叶的肝动脉和门静脉分支。缺血120或180分钟后对肝脏进行再灌注。同时,通过肠系膜上静脉注射重组人TFPI(4mg/kg)。在再灌注后5、12和24小时处死大鼠,并收集肝脏组织。用单克隆抗体(HTF-K108)通过免疫组织化学染色研究TF表达。
在缺血120和180分钟后,检查了5天内的存活率。120分钟缺血组的10只大鼠中有7只(n=10)存活,而180分钟缺血组的10只大鼠中只有1只(10%)存活(n=10)。然而,通过TFPI治疗,120分钟缺血组的所有大鼠(n=10)和180分钟缺血组的6只大鼠(n=10)存活(P<0.05)。缺血前丙氨酸转氨酶(ALT)和凝血酶 - 抗凝血酶复合物(TAT)的血清浓度分别为30.0±2.3IU/L和4.7±1.4ng/ml(n=5)。这些水平在再灌注后3 - 5小时达到峰值(ALT:13909±1900IU/L,TAT:30.4±7.0ng/ml)(P<0.01)。然而,通过TFPI治疗,两个峰值水平均降低(ALT:6017±1290IU/L,TAT:5.4±2.1ng/ml)(P<0.01)。虽然在对照组中TF在聚集到坏死部位的内皮细胞和库普弗细胞上被强烈染色,但在TFPI治疗组中坏死面积和TF染色程度明显降低。
这些结果表明TFPI强烈抑制缺血再灌注损伤,并证实TF在缺血再灌注损伤的发展中起关键作用。